A fatty acid oxidation-dependent metabolic shift regulates the adaptation of BRAF-mutated melanoma to MAPK inhibitors

PURPOSE: Treatment of BRAF(V600E)-mutant melanomas with mitogen-activated protein kinase inhibitors (MAPKi) results in significant tumor regression, but acquired resistance is pervasive. To understand non-mutational mechanisms underlying the adaptation to MAPKi and to identify novel vulnerabilities...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Aloia, Andrea, Müllhaupt, Daniela, Chabbert, Christophe D., Eberhart, Tanja, Flückiger-Mangual, Stefanie, Vukolic, Ana, Eichhoff, Ossia, Irmisch, Anja, Alexander, Leila T., Scibona, Ernesto, Frederick, Dennie T., Miao, Benchun, Tian, Tian, Cheng, Chaoran, Kwong, Lawrence N., Wei, Zhi, Sullivan, Ryan J., Boland, Genevieve M., Herlyn, Meenhard, Flaherty, Keith T., Zamboni, Nicola, Dummer, Reinhard, Zhang, Gao, Levesque, Mitchell P., Krek, Wilhelm, Kovacs, Werner J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6906212/
https://ncbi.nlm.nih.gov/pubmed/31375515
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-0253
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados